Motixafortide vs Plerixafor
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Myeloma
Shared mechanism: CXCR4 · full Multiple Myeloma pipeline
Motixafortide
Marketed by Ayrmid Ltd. and partners
NCT03246529 · Phase 3 · active, not recruiting
GENESIS was a randomized, double-blind, placebo-controlled Phase 3 trial in patients with multiple myeloma. In Part 2, 122 patients were randomized 2:1 to motixafortide (n=80) or placebo (n=42), each given with filgrastim. The single primary endpoint was the proportion of patients who collected at least 6 x 10^6 CD34+ cells/kg in up to 2 aphereses, read by the central laboratory. The FDA label reports 67.5% with motixafortide and 9.5% with placebo (p < 0.0001), so the primary endpoint was met. The endpoint is a stem-cell collection count, which is a surrogate for transplant outcomes. Source: the APHEXDA US label, section 14, and the ClinicalTrials.gov posted results.
Next expected readout: December 2026 · NCT07101445 (registry estimate)
Reported efficacy
Percentage of Subjects Mobilizing ≥6 × 10^6 CD34+ Cells/kg With up to 2 Apheresis Sessions (From first day of study treatment (G-CSF) until day of second apheresis which was planned to occur on Day 6): Proportion of patients who collected at least 6 x 10^6 CD34+ cells/kg in up to 2 aphereses (central laboratory), randomized Part 2, motixafortide + filgrastim (n=80) vs placebo + filgrastim (n=42): 67.5% vs 9.5%, adjusted difference 56.8%, p < 0.0001 (stratified Cochran-Mantel-Haenszel; APHEXDA US label, section 14). CT.gov posted results for the same randomized groups give 70.0% vs 14.3%, p < 0.0001 (Cochran-Mantel-Haenszel). (met)
Result source: NCT03246529
Plerixafor
Marketed by Sanofi
NCT00103662 · Phase 3 · completed
This randomized, double-blind, placebo-controlled Phase 3 trial treated 302 patients with multiple myeloma with G-CSF plus plerixafor or G-CSF plus placebo for stem cell mobilization before autologous transplant. The primary endpoint was the percentage of patients who collected at least 6 x 10^6 CD34+ cells/kg in 2 or fewer aphereses. It was reached by 71.6% with plerixafor vs 34.4% with placebo (P<.001), so the primary was met. Source: DiPersio et al., Blood 2009.
Reported efficacy
Proportion of Participants Achieving a Target of ≥ 6*10^6 CD34+ Cells/kg in 2 or Fewer Days of Apheresis. (up to Day 6): Collection of at least 6 x 10^6 CD34+ cells/kg in 2 or fewer aphereses: plerixafor plus G-CSF 71.6% (106/148) vs placebo plus G-CSF 34.4% (53/154), P<.001 (DiPersio et al., Blood 2009). (met)
Result source: NCT00103662
Results for Multiple Myeloma
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Motixafortide | Plerixafor |
|---|---|---|
| PFS, median | —Trial running · NCT03246529 | —Not posted · NCT00838357 |
| OS, median | —Trial running · NCT03246529 | —Not posted · NCT00838357 |
| ORR | —Trial running · NCT03246529 | —Not posted · NCT00838357 |
| VGPR or better | —Trial running · NCT03246529 | —Not posted · NCT00838357 |
| MRD negativity | —Trial running · NCT03246529 | —Not posted · NCT00838357 |
PFS, median
- Motixafortide
- —Trial running · NCT03246529
- Plerixafor
- —Not posted · NCT00838357
OS, median
- Motixafortide
- —Trial running · NCT03246529
- Plerixafor
- —Not posted · NCT00838357
ORR
- Motixafortide
- —Trial running · NCT03246529
- Plerixafor
- —Not posted · NCT00838357
VGPR or better
- Motixafortide
- —Trial running · NCT03246529
- Plerixafor
- —Not posted · NCT00838357
MRD negativity
- Motixafortide
- —Trial running · NCT03246529
- Plerixafor
- —Not posted · NCT00838357
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
3 other shared endpoints and safety
Coverage. Motixafortide: 7 of 7 rows · Plerixafor: 6 of 7 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Motixafortide Rows use multiple source trials | Plerixafor Rows use multiple source trials |
|---|---|---|
| CD34 Target Achievement event count · % of participants No placebo or comparator arm | 91.7% (n=24) @ 0.29wk*a,b,c,d NCT02639559 · Phase 2 · converted to % from 22 Participants as posted show 1 more dose100% (n=9) @ 0.29wk* NCT02639559 · Phase 2 · converted to % from 9 Participants as posted | 75% (n=20) @ 0.714wk*b,c,d NCT00901225 · Phase 2 · registry result, not featured evidence · combination · converted to % from 15 participants as posted |
| Time to Neutrophil Engraftment Median time to event · months | 0.39 vs 0.39 placebo months*a,e,b,f NCT03246529 · Phase 3 · combination · Multiple Myeloma · phase 3 · converted to months from 12 days as posted show 1 more dose0.39 vs 0.39 placebo months* NCT03246529 · Phase 3 · combination · Multiple Myeloma · phase 3 · converted to months from 12 days as posted | 0.36 vs 0.38 Filgrastim (Neupogen) months*e,b,f NCT02098109 · Phase 2 · registry result, not featured evidence · combination · converted to months from 11 days as posted |
| Time to Platelet Engraftment Median time to event · months | 0.56 vs 0.56 placebo months*a,f NCT03246529 · Phase 3 · combination · Multiple Myeloma · phase 3 · converted to months from 17 days as posted show 1 more dose0.59 vs 0.56 placebo months* NCT03246529 · Phase 3 · combination · Multiple Myeloma · phase 3 · converted to months from 18 days as posted | 0.59 vs 0.59 placebo months @ 56.5wk*f NCT00103662 · Phase 3 · combination · Multiple Myeloma · phase 3 · converted to months from 18 days as posted 1 other source trial0.59 vs 0.57 Filgrastim (Neupogen) months* NCT02098109 · Phase 2 · registry result, not featured evidence · combination · converted to months from 18 days as posted |
| Dropout rate | —BL-8040 + G-CSF (Part 2)g NCT03246529 · Phase 3 · combination · Multiple Myeloma · phase 3 show 3 more results0%BL-8040 + G-CSF Part 1 NCT03246529 · Phase 3 · combination · Multiple Myeloma · phase 3 7.5%BL-8040 + G-CSF Part 2 NCT03246529 · Phase 3 · combination · Multiple Myeloma · phase 3 4% NCT02639559 · Phase 2 | 12.8%h NCT00103662 · Phase 3 · combination · Multiple Myeloma · phase 3 show 17 more results—Arm D: PLERIXAFOR & G-CSF NCT01146834 · Phase 3 · registry result, not featured evidence —Arm E: PLERIXAFOR, VELCADE, & G-CS NCT01146834 · Phase 3 · registry result, not featured evidence · combination 0% NCT04552743 · Phase 2 · registry result, not featured evidence · combination 6.1% NCT02098109 · Phase 2 · registry result, not featured evidence · combination 0% NCT00998049 · Phase 2 · registry result, not featured evidence 4.8% NCT00901225 · Phase 2 · registry result, not featured evidence · combination 0%Multiple Myeloma (MM) NCT00396266 · Phase 2 · registry result, not featured evidence · combination 0%Non-Hodgkin's Lymphoma (NHL) NCT00396266 · Phase 2 · registry result, not featured evidence · combination 6.5%Multiple Myeloma (MM) NCT00322842 · Phase 2 · registry result, not featured evidence 50%Non-Hodgkin's Lymphoma (NHL) NCT00322842 · Phase 2 · registry result, not featured evidence —Multiple Myeloma (MM): Low CD34+ C NCT00322387 · Phase 2 · registry result, not featured evidence · combination —Multiple Myeloma (MM): Plerixafor NCT00322387 · Phase 2 · registry result, not featured evidence · combination —Multiple Myeloma (MM): Plerixafor NCT00322387 · Phase 2 · registry result, not featured evidence · combination —Multiple Myeloma (MM): Plerixafor NCT00322387 · Phase 2 · registry result, not featured evidence · combination —Non-Hodgkin's Lymphoma (NHL): Pler NCT00322387 · Phase 2 · registry result, not featured evidence · combination —Non-Hodgkin's Lymphoma (NHL): Pler NCT00322387 · Phase 2 · registry result, not featured evidence · combination —Non-Hodgkin's Lymphoma (NHL): Pler NCT00322387 · Phase 2 · registry result, not featured evidence · combination |
| Discontinued due to AEs | —BL-8040 + G-CSF (Part 2)g NCT03246529 · Phase 3 · combination · Multiple Myeloma · phase 3 show 3 more results0%BL-8040 + G-CSF Part 1 NCT03246529 · Phase 3 · combination · Multiple Myeloma · phase 3 2.5%BL-8040 + G-CSF Part 2 NCT03246529 · Phase 3 · combination · Multiple Myeloma · phase 3 — NCT02639559 · Phase 2 | —h NCT00103662 · Phase 3 · combination · Multiple Myeloma · phase 3 show 17 more results—Arm D: PLERIXAFOR & G-CSF NCT01146834 · Phase 3 · registry result, not featured evidence —Arm E: PLERIXAFOR, VELCADE, & G-CS NCT01146834 · Phase 3 · registry result, not featured evidence · combination — NCT04552743 · Phase 2 · registry result, not featured evidence · combination — NCT02098109 · Phase 2 · registry result, not featured evidence · combination — NCT00998049 · Phase 2 · registry result, not featured evidence — NCT00901225 · Phase 2 · registry result, not featured evidence · combination —Multiple Myeloma (MM) NCT00396266 · Phase 2 · registry result, not featured evidence · combination —Non-Hodgkin's Lymphoma (NHL) NCT00396266 · Phase 2 · registry result, not featured evidence · combination —Multiple Myeloma (MM) NCT00322842 · Phase 2 · registry result, not featured evidence —Non-Hodgkin's Lymphoma (NHL) NCT00322842 · Phase 2 · registry result, not featured evidence —Multiple Myeloma (MM): Low CD34+ C NCT00322387 · Phase 2 · registry result, not featured evidence · combination —Multiple Myeloma (MM): Plerixafor NCT00322387 · Phase 2 · registry result, not featured evidence · combination —Multiple Myeloma (MM): Plerixafor NCT00322387 · Phase 2 · registry result, not featured evidence · combination —Multiple Myeloma (MM): Plerixafor NCT00322387 · Phase 2 · registry result, not featured evidence · combination —Non-Hodgkin's Lymphoma (NHL): Pler NCT00322387 · Phase 2 · registry result, not featured evidence · combination —Non-Hodgkin's Lymphoma (NHL): Pler NCT00322387 · Phase 2 · registry result, not featured evidence · combination —Non-Hodgkin's Lymphoma (NHL): Pler NCT00322387 · Phase 2 · registry result, not featured evidence · combination |
| Serious AEs | 8.8%BL-8040 + G-CSF (Part 2)g NCT03246529 · Phase 3 · combination · Multiple Myeloma · phase 3 show 3 more results8.3%BL-8040 + G-CSF Part 1 NCT03246529 · Phase 3 · combination · Multiple Myeloma · phase 3 —BL-8040 + G-CSF Part 2 NCT03246529 · Phase 3 · combination · Multiple Myeloma · phase 3 0% NCT02639559 · Phase 2 | 2.7%h NCT00103662 · Phase 3 · combination · Multiple Myeloma · phase 3 show 17 more results—Arm D: PLERIXAFOR & G-CSF NCT01146834 · Phase 3 · registry result, not featured evidence —Arm E: PLERIXAFOR, VELCADE, & G-CS NCT01146834 · Phase 3 · registry result, not featured evidence · combination 0% NCT04552743 · Phase 2 · registry result, not featured evidence · combination 4.3% NCT02098109 · Phase 2 · registry result, not featured evidence · combination 0% NCT00998049 · Phase 2 · registry result, not featured evidence 0% NCT00901225 · Phase 2 · registry result, not featured evidence · combination 14.3%Multiple Myeloma (MM) NCT00396266 · Phase 2 · registry result, not featured evidence · combination 12.5%Non-Hodgkin's Lymphoma (NHL) NCT00396266 · Phase 2 · registry result, not featured evidence · combination 0%Multiple Myeloma (MM) NCT00322842 · Phase 2 · registry result, not featured evidence 50%Non-Hodgkin's Lymphoma (NHL) NCT00322842 · Phase 2 · registry result, not featured evidence 0%Multiple Myeloma (MM): Low CD34+ C NCT00322387 · Phase 2 · registry result, not featured evidence · combination 22.2%Multiple Myeloma (MM): Plerixafor NCT00322387 · Phase 2 · registry result, not featured evidence · combination 25%Multiple Myeloma (MM): Plerixafor NCT00322387 · Phase 2 · registry result, not featured evidence · combination 16.7%Multiple Myeloma (MM): Plerixafor NCT00322387 · Phase 2 · registry result, not featured evidence · combination 0%Non-Hodgkin's Lymphoma (NHL): Pler NCT00322387 · Phase 2 · registry result, not featured evidence · combination 0%Non-Hodgkin's Lymphoma (NHL): Pler NCT00322387 · Phase 2 · registry result, not featured evidence · combination 14.3%Non-Hodgkin's Lymphoma (NHL): Pler NCT00322387 · Phase 2 · registry result, not featured evidence · combination |
| Most frequent reported AEs | g injection site pain 50% (placebo 4.8%) pruritus 32.5% (placebo 0%) injection site erythema 27.5% (placebo 0%) NCT03246529 · Phase 3 · combination · Multiple Myeloma · phase 3 show 2 more resultsinjection site pain 75% (placebo 4.8%) pruritus 66.7% (placebo 0%) injection site pruritus 41.7% (placebo 0%) NCT03246529 · Phase 3 · combination · Multiple Myeloma · phase 3 lymphocyte count increased 88% platelet count decreased 88% allergic reaction 80% NCT02639559 · Phase 2 | h bone pain 36.1% (placebo 42.4%) nausea 34.7% (placebo 25.8%) diarrhoea 32% (placebo 19.2%) NCT00103662 · Phase 3 · combination · Multiple Myeloma · phase 3 show 15 more resultspain 52% paresthesia 28% nausea 24% NCT04552743 · Phase 2 · registry result, not featured evidence · combination bone pain 41.3% lymphocyte count decreased 39.1% platelet count decreased 39.1% NCT02098109 · Phase 2 · registry result, not featured evidence · combination nausea 43.6% diarrhea 25.6% dizziness 20.5% NCT00998049 · Phase 2 · registry result, not featured evidence febrile neutropenia 19% NCT00901225 · Phase 2 · registry result, not featured evidence · combination diarrhoea 50% bone pain 42.9% catheter site erythema 42.9% NCT00396266 · Phase 2 · registry result, not featured evidence · combination back pain 50% injection site erythema 50% paraesthesia 50% NCT00396266 · Phase 2 · registry result, not featured evidence · combination hypokalaemia 16.1% nausea 9.7% pyrexia 9.7% NCT00322842 · Phase 2 · registry result, not featured evidence asthenia 25% diarrhoea 25% lymphadenopathy 25% NCT00322842 · Phase 2 · registry result, not featured evidence diarrhoea 100% headache 100% hypoaesthesia oral 100% NCT00322387 · Phase 2 · registry result, not featured evidence · combination bone pain 77.8% nausea 77.8% catheter related complication 33.3% NCT00322387 · Phase 2 · registry result, not featured evidence · combination back pain 50% genital lesion 25% kyphosis 25% NCT00322387 · Phase 2 · registry result, not featured evidence · combination bone pain 58.3% diarrhoea 50% nausea 50% NCT00322387 · Phase 2 · registry result, not featured evidence · combination thrombocytopenia 50% back pain 33.3% bone pain 33.3% NCT00322387 · Phase 2 · registry result, not featured evidence · combination anal fistula 100% catheter site erythema 100% haemorrhoids 100% NCT00322387 · Phase 2 · registry result, not featured evidence · combination headache 71.4% bone pain 57.1% nausea 57.1% NCT00322387 · Phase 2 · registry result, not featured evidence · combination |
Notes
- aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- bPopulation context differs: registered conditions differ.
- cTreatment context has not been resolved for both arms.
- dAssessment timepoints differ: 0.29 weeks versus 0.714 weeks.
- eTrial phases differ: Phase 3 versus Phase 2.
- fThe assessment timepoint is not available for both results.
- gPopulation comparability has not been reviewed for 1 of these studies.
- hPopulation comparability has not been reviewed for 17 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Motixafortide
show 3 more results
Plerixafor
show 2 more results
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 2 more results
+ 18 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Motixafortide's landscape · Plerixafor's landscape